Education
About Us
Working with TipRanks
Follow Us
Quince Therapeutics (QNCX)
NASDAQ:QNCX
QNCX Stock Chart & Stats
$0.61
-$0.07(-3.61%)
At close: 4:00 PM EST
$0.61
-$0.07(-3.61%)
Day’s Range― - ―
52-Week Range$0.13 - $4.55
Previous CloseN/A
Volume30.57K
Average Volume (3M)5.06M
Market Cap
$33.97M
Enterprise Value$22.68M
Total Cash (Recent Filing)$26.29M
Total Debt (Recent Filing)$17.99M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Mar 03, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding55,681,490
10 Day Avg. Volume13,215,477
30 Day Avg. Volume5,057,723
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.52
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-190.57
Enterprise Value/Ebitda-0.41
Forecast
1Y Price Target
$10.00Price Target Upside1539.34% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Safety ProfileAnalyst notes the drug demonstrated a tolerable safety profile with no clinically meaningful safety concerns identified, which may reduce regulatory safety risk.
Patient RetentionAnalyst points out that all patients who completed the NEAT study elected to join the open-label extension, signaling strong patient confidence and potential for longer-term uptake.
Platform And Indication ExpansionAnalyst highlights eDSP's use of the AIDE technology platform and planned expansion into Duchenne muscular dystrophy and other indications, creating multiple development and commercial pathways.
Bears Say
Clinical Efficacy FailureAnalyst reports the Phase 3 NEAT study missed both the primary and key secondary endpoints, undermining the drug's efficacy case and core value proposition.
Development Halt And Strategic UncertaintyAnalyst notes management has halted clinical development of the program and is evaluating strategic options while conserving cash, creating uncertainty about the company's development path.
Financial Outlook And Analyst ReactionAnalyst cut the rating to Hold and removed expected revenue from the failed program, materially reducing projected future revenue and altering expense assumptions.
Quince Therapeutics News
QNCX FAQ
What was Quince Therapeutics’s price range in the past 12 months?
Quince Therapeutics lowest stock price was $0.13 and its highest was $4.55 in the past 12 months.
What is Quince Therapeutics’s market cap?
Quince Therapeutics’s market cap is $33.97M.
When is Quince Therapeutics’s upcoming earnings report date?
Quince Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 17 days.
How were Quince Therapeutics’s earnings last quarter?
Quince Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.215 by -$0.035.
Is Quince Therapeutics overvalued?
According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued.
Does Quince Therapeutics pay dividends?
Quince Therapeutics does not currently pay dividends.
What is Quince Therapeutics’s EPS estimate?
Quince Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Quince Therapeutics have?
Quince Therapeutics has 55,681,490 shares outstanding.
What happened to Quince Therapeutics’s price movement after its last earnings report?
Quince Therapeutics reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.215. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Quince Therapeutics?
Currently, no hedge funds are holding shares in QNCX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quince Therapeutics
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
QNCX Stock 12 Month Forecast
Average Price Target
$10.00
▲(1539.34% Upside)
Technical Analysis
Ownership Overview
14.86% Insiders
3.26% Mutual Funds
9.26% Other Institutional Investors
69.27% Public Companies and
Individual Investors